Cargando…

Real-World Treatments and Clinical Outcomes in Advanced NSCLC without Actionable Mutations after Introduction of Immunotherapy in Japan

SIMPLE SUMMARY: The aim of this study was to evaluate treatment patterns and real-world clinical outcomes since immunotherapy was introduced in Japan as the initial (first-line) therapy for treating patients with lung cancer, the leading cause of cancer-related deaths in Japan. For 1182 patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nokihara, Hiroshi, Kijima, Takashi, Yokoyama, Toshihide, Kagamu, Hiroshi, Suzuki, Takuji, Mori, Masahide, Santorelli, Melissa L., Taniguchi, Kazuko, Kamitani, Tetsu, Irisawa, Masato, Kanda, Kingo, Abe, Machiko, Burke, Thomas, Goto, Yasushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220782/ https://www.ncbi.nlm.nih.gov/pubmed/35740512 http://dx.doi.org/10.3390/cancers14122846

Ejemplares similares

First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan
por: Goto, Yasushi, et al.
Publicado: (2022)

Health Care Resource Use Among Patients with Advanced Non–Small Cell Lung Cancer in Japan, 2017–2019
por: Goto, Yasushi, et al.
Publicado: (2023)

Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies
por: Tanaka, Midori, et al.
Publicado: (2018)

Five‐year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non‐small‐cell lung cancer
por: Kanda, Shintaro, et al.
Publicado: (2020)

Real‐world outcomes of pembrolizumab monotherapy in non‐small cell lung cancer in Japan: A post‐marketing surveillance
por: Yamamoto, Nobuyuki, et al.
Publicado: (2022)

Circulating cell-free plasma tumour DNA shows a higher incidence of EGFR mutations in patients with extrathoracic disease progression
por: Seki, Yoshitaka, et al.
Publicado: (2018)

The Long Half-Life of Programmed Cell Death Protein 1 Inhibitors May Increase the Frequency of Immune-Related Adverse Events After Subsequent EGFR Tyrosine Kinase Inhibitor Therapy
por: Shinno, Yuki, et al.
Publicado: (2020)

Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma
por: Tamura, Yosuke, et al.
Publicado: (2015)

Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism
por: Fujiwara, Yutaka, et al.
Publicado: (2016)

A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC)
por: Mizugaki, Hidenori, et al.
Publicado: (2015)

Potential of VEGFR2 expression as a predictive marker of PD-1 blockade in patients with advanced NSCLC
por: Kaira, Kyoichi, et al.
Publicado: (2022)

Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR ‐major mutant NSCLC receiving osimertinib
por: Kaira, Kyoichi, et al.
Publicado: (2023)

Tensile Strength of Porcine Aorta Decellularized with Liquefied Dimethyl Ether and DNase
por: Kanda, Hideki, et al.
Publicado: (2022)

A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan
por: Goto, Yasushi, et al.
Publicado: (2023)

A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors
por: Nokihara, Hiroshi, et al.
Publicado: (2012)

Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study
por: Kawachi, Hayato, et al.
Publicado: (2022)

Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
por: Yamaguchi, Ou, et al.
Publicado: (2020)

Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan
por: Edahiro, Ryuya, et al.
Publicado: (2019)

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
por: Yamaguchi, Ou, et al.
Publicado: (2023)

Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma
por: Imakura, Takeshi, et al.
Publicado: (2021)

Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study)
por: Morikawa, Kei, et al.
Publicado: (2020)

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
por: Takumida, Hiroshi, et al.
Publicado: (2021)

Imaging hamster model of bile duct cancer in vivo using fluorescent l-glucose derivatives
por: Yokoyama, Hiroshi, et al.
Publicado: (2016)

THE RELATION OF THE SPLEEN TO BLOOD DESTRUCTION AND REGENERATION AND TO HEMOLYTIC JAUNDICE : XVI. THE INFLUENCE OF SPLENECTOMY AND OF BLOOD DISINTEGRATION UPON THE PRODUCTION OF BILE PIGMENT.
por: Goto, Kingo
Publicado: (1917)

A STUDY OF THE NITROGEN METABOLISM AND OF ACIDOSIS AFTER THE TRANSPLANTATION OF A URETER INTO THE DUODENUM IN DOGS
por: Goto, Kingo
Publicado: (1918)

EXPERIMENTAL ACUTE NEPHRITIS : A STUDY OF THE ACIDOSIS, NITROGEN AND CHLORIDE RETENTION, AND OF THE PROTECTIVE ACTION OF SODIUM BICARBONATE.
por: Goto, Kingo
Publicado: (1918)

A STUDY OF THE ACIDOSIS, BLOOD UREA, AND PLASMA CHLORIDES IN URANIUM NEPHRITIS IN THE DOG, AND OF THE PROTECTIVE ACTION OF SODIUM BICARBONATE
por: Goto, Kingo
Publicado: (1917)

Parkinson's Disease-Related Protein, α-Synuclein, in Malignant Melanoma
por: Matsuo, Yasuhiro, et al.
Publicado: (2010)

Adapting the Motivated Strategies for Learning Questionnaire to the Japanese Problem-Based Learning Context: A Validation Study
por: Nomura, Osamu, et al.
Publicado: (2023)

Value of (18)F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Advanced Research on Immune Checkpoint Inhibitor Therapy
por: Imai, Hisao, et al.
Publicado: (2022)

Heterogeneity of metabolic adaptive capacity affects the prognosis among pancreatic ductal adenocarcinomas
por: Kanda, Taishu, et al.
Publicado: (2022)

The Effect of High Sodium Concentration on the Action Potential of the Skate Heart
por: Seyama, Issei, et al.
Publicado: (1967)

Correlation of Body Composition and Nutritional Status with Functional Recovery in Stroke Rehabilitation Patients
por: Irisawa, Hiroshi, et al.
Publicado: (2020)

Assessment of changes in muscle mass, strength, and quality and activities of daily living in elderly stroke patients
por: Irisawa, Hiroshi, et al.
Publicado: (2022)

Relationship between Nutritional Status, Body Composition, Muscle Strength, and Functional Recovery in Patients with Proximal Femur Fracture
por: Irisawa, Hiroshi, et al.
Publicado: (2022)

Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset
por: Kiura, Katsuyuki, et al.
Publicado: (2018)

Improved Immunodetection of Endogenous α-Synuclein
por: Lee, Byung Rho, et al.
Publicado: (2011)

Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
por: Seki, Yoshitaka, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ufd00add5mkhbcdc94k0hcm1di